Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myeloma
Lust, John A., Lacy, Martha Q. , Zeldenrust, Steven R., Moon‐Tasson, Laurie L., Dinarello, Charles A. , Donovan, Kathleen A., Moon-Tasson, Laurie L, Witzig, Thomas E.

American Journal of Hematology | March 6, 2016 | Volume: 91 | Issue: 6 | Pages: 571-574

10.1002/ajh.24352 | PMID 26945843 Get It

We report the long‐term follow‐up results of a phase II trial of IL‐1 receptor antagonist and low‐dose dexamethasone for early stage multiple myeloma (MM). Patients were eligible if they had smoldering multiple myeloma (SMM) or indolent multiple myeloma (IMM) without the need for immediate therapy. Forty seven patients were enrolled and subsequently treated with IL‐1Ra; in 25/47 low‐dose dexamethasone (20 mg weekly) was added. The primary endpoint was progression‐free survival (PFS). In the clinical trial, three patients achieved a minor response (MR) to IL‐1Ra alone; five patients a partial response (PR) and four patients an MR after addition of dexamethasone. Seven patients showed a decrease in the plasma cell labeling index (PCLI) which paralleled a decrease in the high sensitivity C‐reactive protein (hs‐CRP). The median PFS for the 47 patients was 1116 days (37.2 months). The median PFS for patients without (n = 22) and with (n = 25) a decrease in their baseline hs‐CRP was 326 days (11 months) vs. 3139 days (104 months) respectively (P <0.0001). The median overall survival (OS) for the 47 patients was 3482 days (9.5 years). The median OS for patients without and with a decrease in their baseline hs‐CRP was 2885 days (7.9 years) vs. median not reached, respectively (P = 0.001). In SMM/IMM patients at risk for progression to active myeloma, reduction in the hs‐CRP indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved PFS and OS.(Clinical Trials.gov Identifier: NCT00635154) Am. J. Hematol. 91:571–574, 2016. © 2016 Wiley Periodicals, Inc.
Clostridium difficile infection after restorative proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis
Ugarte, Maria L. Martinez, Khanna, Sahil , Pardi, D. S., Dozois, Eric J. , Mathis, Kellie L. , Lightner, Amy L. , Colibaseanu, Dorin

Colorectal Disease | March 6, 2016 | Volume: 18 | Issue: 5 | Pages: No page available

10.1111/codi.13325 | PMID 26945555 Get It

AbstractAimClostridium difficile infection (CDI) of the ileal pouch following restorative proctocolectomy (RPC) is becoming increasingly recognized. We aimed to understand better (i) the associated risk factors, (ii) treatment practices and (iii) the pouch diversion and failure rate in patients who developed CDI of the pouch after RPC for ulcerative colitis (UC).MethodPatients who tested positive for C. difficile of the pouch between 2007 and 2010 were included in the analysis. Data collected included patient demographics, time from RPC to documented CDI, the treatment of CDI and rate of excision of the pouch.ResultsOf 2785 patients recorded in the hospital CDI database, 15 had had an RPC with ileal pouch anal anastomosis. The median age was 44 years and the median interval from RPC to first documented episode of CDI was 3 years. Thirteen (81%) patients had had multiple episodes of pouchitis before and after CDI infection, and all were symptomatic at the time of testing for CDI. Within 30 days of the diagnosis of CDI, six (40%) patients were taking immunosuppressive medication, seven (47%) were taking a proton pump inhibitor and 12 (80%) had received antibiotics. Five patients required hospitalization for CDI and four had severe infections characterized by a serum creatinine more than 1.5 times baseline (n = 3) and a white cell count above 15 000 (n = 1). Six patients who underwent endoscopy had severe inflammation of the pouch including the presence of a pseudomembrane in one case. Ten patients were treated with metronidazole alone and five with vancomycin. Two patients had recurrent CDI of the pouch during a median follow‐up period of 2.9 years and one had CDI refractory to medical management. This patient required diversion of the pouch with an ileostomy for refractory CDI but no patient required excision of the pouch.ConclusionAll 15 patients developing CDI of the pouch were successfully treated with antibiotics and only one required surgery in the form of an ileostomy.
Baseline features and differences in 48 week clinical outcomes in patients with gastroparesis and type 1 vs type 2 diabetes
Koch, Kenneth L. , Yates, Katherine P. , Pasricha, Pankaj J. , Calles-Escandón, Jorge, Snape, William J., McCallum, Richard W. , Sarosiek, Irene , Farrugia, Gianrico , Tonascia, James , Lee, L., Miriel, Laura , Hamilton, Frank A., Hasler, William L. , Parkman, Henry P. , Abell, Thomas L. , Nguyen, Linda Anh B. , Lee, L.

Neurogastroenterology & Motility | March 6, 2016 | Volume: 28 | Issue: 7 | Pages: 1001-1015

10.1111/nmo.12800 | PMID 26946489 Get It

Abstract Background In studies of diabetic gastroparesis, patients with type 1 and type 2 diabetes mellitus (T1 DM , T2 DM ) are often combined for analyses. We compared gastroparesis severity, healthcare utilization, psychological function, and quality of life in T1 DM vs T2 DM gastroparesis patients. Methods Questionnaire, laboratory, and scintigraphy data from patients with gastroparesis and T1 DM and T2 DM from seven centers of the National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium Registry were compared at enrollment and after 48 weeks. Multiple regression models assessed baseline and follow‐up differences between diabetes subtypes. Key Results At baseline, T1 DM patients ( N = 78) had slower gastric emptying, more hospitalizations, more gastric stimulator implantations, higher hemoglobin A1c (HbA1c), and more anxiety vs T2 DM patients ( N = 59). Independent discriminators of patients with T1 DM vs T2 DM included worse gastroesophageal reflux disease, less bloating, more peripheral neuropathy, and fewer comorbidities ( p ≤ 0.05). On follow‐up, gastrointestinal ( GI ) symptom scores decreased only in T2 DM ( p < 0.05), but not in T1 DM patients who reported greater prokinetic, proton pump inhibitor, anxiolytic, and gastric stimulator usage over 48 weeks ( p ≤ 0.03). Gastrointestinal symptoms at baseline and 48 weeks with both subtypes were not associated with HbA1c, peripheral neuropathy, psychological factors, or quality of life. Conclusions & Inferences Baseline symptoms were similar in T1 DM and T2 DM patients, even though T1 DM patients had worse gastric emptying delays and higher HbA1c suggesting other factors mediate symptom severity. Symptom scores at 48 weeks decreased in T2 DM , but not T1 DM patients, despite increased medical and surgical treatment utilization by T1 DM patients. Defining causes of different outcomes in diabetic gastroparesis warrants further investigation.
Reprogrammed keratinocytes from elderly type 2 diabetes patients suppress senescence genes to acquire induced pluripotency
Ohmine, Seiga, Squillace, Karen A., Hartjes, Katherine A., Deeds, Michael , Armstrong, Adam, Thatava, Tayaramma, Sakuma, Toshie, Kudva, Yogish C. , Ikeda, Yasuhiro , Terzic, André

Aging | March 6, 2016 | Volume: 4 | Issue: 1 | Pages: 60-73

10.18632/aging.100428 | PMID 22308265 Get It

Survival of irradiated recipient mice after transplantation of bone marrow from young, old and “early aging” mice
Guest, Ian, Ilić, Zoran , Scrable, Heidi, Sell, Stewart

Aging | March 6, 2016 | Volume: 7 | Issue: 12 | Pages: 1212-1222

10.18632/aging.100867 | PMID 26796640 Get It

Gene expression of key regulators of mitochondrial biogenesis is sex dependent in mice with growth hormone receptor deletion in liver
Zawada, Ilona, Berryman, Darlene E. , Lewiñski, Andrzej , Kopchick, John J. , Karbownik‐Lewińska, Małgorzata , Gesing, Adam , Stout, Michael B, Masternak, Michal M , List, Edward Owen , Stout, Michael B , Bartke, Andrzej

Aging | March 6, 2016 | Volume: 7 | Issue: 3 | Pages: 195-204

10.18632/aging.100733 | PMID 25855408 Get It

Synergy of cancer immunotherapy and radiotherapy
Mansfield, Aaron S. , Park, Sean S. , Dong, Haidong , Mansfield, Aaron S

Aging | March 6, 2016 | Volume: 7 | Issue: 3 | Pages: 144-145

10.18632/aging.100730 | PMID 25868470 Get It

Cardiac BNP gene delivery prolongs survival in aged spontaneously hypertensive rats with overt hypertensive heart disease
Tonne, Jason M., Holditch, Sara J., Oehler, Elise A., Schreiber, Claire A., Ikeda, Yasuhiro , Cataliotti, Alessandro

Aging | March 6, 2016 | Volume: 6 | Issue: 4 | Pages: 311-319

10.18632/aging.100655 | PMID 24799459 Get It

Altered behavioral and metabolic circadian rhythms in mice with disrupted NAD+ oscillation
Sahar, Saurabh, Nin, Verónica , Barbosa, Maria Thereza , Chini, Eduardo N. , Sassone‐Corsi, Paolo

Aging | March 6, 2016 | Volume: 3 | Issue: 8 | Pages: 794-802

10.18632/aging.100368 | PMID 21937766 Get It